文献速递免疫规划慢病防控与筛查

重度慢性肾病成人对A型流感嗜血杆菌的自然免疫与B细胞亚群

Natural immunity against Haemophilus influenzae type a and B-cell subpopulations in adult patients with severe chronic kidney disease.
PubMed 文献 · Vaccine · 2019-05-20

患者血清杀菌活性滴度低于对照,但72%患者可检出杀菌活性、100%可检出IgG和IgM抗体。数据提示Hia结合疫苗可能通过再激活免疫记忆在成人慢性肾病患者中具有免疫原性。

要点

  • 重度慢性肾病患者抗Hia血清杀菌活性滴度低于健康对照。
  • 72%患者可检出抗Hia血清杀菌活性,100%可检出IgG和IgM抗体。
  • Hia结合疫苗可能通过再激活免疫记忆在成人慢性肾病患者中具免疫原性。

核心结论

  • 重度慢性肾病患者对Hia的自然血清杀菌活性低于健康对照,但多数仍可检出杀菌活性及特异性IgG/IgM抗体。
  • 数据提示Hia结合疫苗可能通过再激活针对Hia的免疫记忆在成人慢性肾病患者中具有免疫原性。

研究设计与样本

  • 检测血清杀菌活性、抗Hia荚膜多糖IgG和IgM抗体浓度及B细胞亚群,其中28例慢性肾病患者测定了B细胞亚群比例和绝对数。

主要发现

  • 慢性肾病患者血清杀菌活性滴度低于健康对照。
  • 慢性肾病组与对照组抗Hia IgG或IgM抗体浓度无显著差异,但原住民患者IgM抗体浓度高于非原住民患者。
  • 慢性肾病患者CD19+ B细胞和类别转换记忆B细胞(CD19+CD27+IgM-)比例高于健康对照,CD19+CD27-IgM- B细胞比例低于健康对照。
  • 非原住民慢性肾病患者IgM记忆B细胞和CD19+CD27-IgM- B细胞比例显著高于原住民患者,绝对数无显著差异。
  • 72%慢性肾病患者可检出血清杀菌活性滴度,100%可检出IgG和IgM抗体。

临床怎么用

  • 在重度慢性肾病成人中评估Hia疫苗时,可关注自然抗体与记忆B细胞作为免疫原性潜在参考。
  • 对原住民与非原住民慢性肾病患者,IgM抗体和B细胞亚群分布存在差异,评估疫苗反应时需考虑人群背景。

局限性

  • B细胞亚群比例和绝对数仅在28例慢性肾病患者中测定。
  • 原文未报告血清杀菌活性滴度、抗体浓度及B细胞亚群的具体数值和统计检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Individuals suffering from severe chronic kidney disease (CKD) are immunocompromised and therefore highly susceptible to various infections including Haemophilus influenzae type a (Hia), an emerging pathogen in North American Indigenous populations. Immunocompromised Indigenous adults are considered a target for a new Hia vaccine under development. In an attempt to foresee their response to Hia immunization, we studied natural immunity against Hia and B-cell subpopulations in sixty patients with CKD residing in a geographic region with noticeable presence of Hia invasive disease. Serum bactericidal activity (SBA) against Hia, concentrations of IgG and IgM antibodies specific to Hia capsular polysaccharide, and B-cell subpopulations were studied in patients with CKD and 35 healthy controls of the same age. Of the patients with CKD, proportions and absolute numbers of B-cell subpopulations were determined for 28 patients. The patients had lower SBA titres compared to controls. Although no significant differences in anti-Hia IgG or IgM antibody concentrations between control and CKD groups were found, IgM antibody concentrations were higher in Indigenous than non-Indigenous patients. Patients with CKD had a higher proportion of B cells (CD19+), class switched memory B cells (CD19+CD27+IgM-) and a lower proportion of CD19+CD27-IgM- B cells compared to healthy controls. Non-Indigenous patients with CKD had significantly higher proportions of IgM memory B cells and CD19+CD27-IgM- B cells compared to Indigenous patients with no significant difference in absolute numbers. Because 72% of CKD patients had detectable SBA titres and 100% had detectable IgG and IgM antibodies it is possible that a portion of IgM memory B cells and class switched memory B cells are specific for Hia resulting from a natural exposure to the pathogen. The data suggest that a Hia-conjugate vaccine may be immunogenic in adult patients with CKD as it will potentially induce re-activation of immunological memory against Hia.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gaultier GN, McCready W, Ulanova M, et al. Natural immunity against Haemophilus influenzae type a and B-cell subpopulations in adult patients with severe chronic kidney disease. Vaccine. 2019. PMID: 31122854. doi:10.1016/j.vaccine.2019.05.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。